Conversely, large observational studies have not consistently demonstrated increased gastroparesis incidence compared to other diabetes therapies when accounting for confounding factors
In terms of tolerability, GLP-1RAs are commonly associated with GI side effects, which are often dose-dependent and time-limiting [55]
1, 2026, Aetna no longer offers individual or family plans through the Affordable Care Act marketplace
doi:10.1158/2767-9764.CRC-25-0554 Mavromatis LA, Surapaneni A, Mehta S, et al: Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study
13, 2023, manufactures two GLP-1 drugs known as Wegovy and Ozempic, two well-known therapeutics in the space